Morgan Stanley’s AgomAb Therapeutics NV AGMB Stock Holding History
Bought
Maintained
Sold
Other funds holding AGMB
SL
Morgan Stanley's AGMB Position: Q3 2026 in Review
Morgan Stanley increased its AgomAb Therapeutics NV (AGMB) stake by 412% in Q3 2026, buying an estimated $64K and bringing the position to 6,146 shares worth $68.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6465.
Morgan Stanley first reported a position in AGMB in Q1 2026 and has held it in 3 quarters since. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.
- Morgan Stanley held 6,146 shares of AgomAb Therapeutics NV worth $68.2K as of Q3 2026.
- Morgan Stanley bought 4,946 AgomAb Therapeutics NV shares in Q3 2026, an estimated $64K.
- AgomAb Therapeutics NV made up ﹤0.01% of Morgan Stanley's portfolio in Q3 2026, its #6465 holding.
- Morgan Stanley first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 3 quarters since.
- 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.
Based on Morgan Stanley's 13F filing for Q3 2026, filed 13 Nov 2026.